Cochrane · systematic review · CD003129
Methotrexate for juvenile idiopathic arthritis
Tan, J, Renton, WD, Whittle, SL, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
24
current version
GRADE rated
13
No studies
11
Included studies
NR
No studies 11 · 45.8%Ungraded 0 · 0%Very low 1 · 4.2%Low 12 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Methotrexate compared with placebo in children and young people with juvenile idiopathic arthritis
Population: children and young people with JIA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes(time frame of absolute effects) Methotrexate vs placebo | no estimate extracted | NR | No studies |
Treatment responsea(up to 6 months) Methotrexate vs placebo | RR 1.67 [1.21, 2.31] | 3 studies · 328 participants | Low Downgraded: imprecision, indirectness |
Sustained clinically inactive diseasec Methotrexate vs placebo | no estimate extracted | NR | No studies |
Function Methotrexate vs placebo | no estimate extracted | NR | No studies |
Pain Mean improvement in pain on motion from baseline, 0–100 scale, 0 represents no pain(up to 6 months) Methotrexate vs placebo | no estimate extracted | 1 study · 114 participants | Low Downgraded: imprecision, indirectness |
Participant global assessment of well‐being(up to 6 months) Methotrexate vs placebo | RR 1.23 [0.88, 1.72] | 1 study · 176 participants | Low Downgraded: imprecision, indirectness |
Serious adverse events(up to 6 months) Methotrexate vs placebo | RR 0.63 [0.04, 8.97] | 3 studies · 328 participants | Low Downgraded: imprecision, indirectness |
Withdrawals due to adverse events (up to 6 months) Methotrexate vs placebo | RR 3.46 [0.6, 19.79] | 3 studies · 328 participants | Low Downgraded: imprecision, indirectness |
Oral methotrexate plus intra‐articular glucocorticoid compared to intra‐articular glucocorticoid alone in children and young people with juvenile idiopathic arthritis
Population: children and young people with JIA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes(time frame of absolute effects) Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone | no estimate extracted | NR | No studies |
Treatment responsea Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone | no estimate extracted | NR | No studies |
Sustained clinically inactive diseaseb(12 months) Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone | RR 1.37 [0.91, 2.06] | 1 study · 207 participants | Low Downgraded: risk of bias, imprecision |
Function Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone | no estimate extracted | NR | No studies |
Pain Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone | no estimate extracted | NR | No studies |
Participant global assessment of well‐being Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone | no estimate extracted | NR | No studies |
Serious adverse events(12 months) Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone | no estimate extracted | NR | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events(12 months) Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone | RR 8.75 [0.48, 160.4] | 1 study · 207 participants | Low Downgraded: risk of bias, imprecision |
Methotrexate compared to alternative disease‐modifying antirheumatic drugs for children and young people with juvenile idiopathic arthritis
Population: children and young people with JIA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes(time frame of absolute effects) Methotrexate vs alternative disease‐modifying antirheumatic drugs | no estimate extracted | NR | No studies |
Treatment responsea(4 months) Methotrexate vs alternative disease‐modifying antirheumatic drugs | RR 1.4 [0.93, 2.1] | 1 study · 94 participants | Low Downgraded: imprecision |
Sustained clinically inactive diseasec Methotrexate vs alternative disease‐modifying antirheumatic drugs | no estimate extracted | NR | No studies |
Function Methotrexate vs alternative disease‐modifying antirheumatic drugs | no estimate extracted | 1 study · 94 participants | Low Downgraded: imprecision |
Pain Methotrexate vs alternative disease‐modifying antirheumatic drugs | no estimate extracted | NR | No studies |
Participant global assessment of well‐being Methotrexate vs alternative disease‐modifying antirheumatic drugs | no estimate extracted | 1 study · 94 participants | Low Downgraded: imprecision |
Serious adverse events(4 months) Methotrexate vs alternative disease‐modifying antirheumatic drugs | RR 0.14 [0.01, 2.69] | 1 study · 94 participants | Low Downgraded: imprecision |
Withdrawals due to adverse events(4 months) Methotrexate vs alternative disease‐modifying antirheumatic drugs | RR 0.33 [0.04, 3.09] | 1 study · 94 participants | Low Downgraded: imprecision |